Cervical cancer is removed through surgery, radiation, chemotherapy, or a combination of these, depending on how far the cancer has spread at diagnosis. When caught early, a relatively minor surgical procedure can eliminate the cancer entirely, with five-year survival rates above 85% for localized disease. As the cancer advances, treatment shifts from surgery alone to radiation combined with chemotherapy, and newer immunotherapy drugs now play a role for cancers that have spread or returned.
How Stage Determines Treatment
Cervical cancer is classified into stages based on tumor size and how far it has spread beyond the cervix. The stage at diagnosis is the single biggest factor in deciding which treatment approach your medical team will recommend. Localized cancer (confined to the cervix) has an 85.6% five-year survival rate. Regional cancer (spread to nearby tissues or lymph nodes) drops to 79.6%. Distant cancer (spread to organs like the lungs or liver) has a 46.6% five-year survival rate, according to data from the National Cancer Institute’s SEER program covering 2015 to 2021.
These numbers reflect averages across all patients. Individual outcomes vary based on age, overall health, tumor biology, and how well the cancer responds to treatment.
Procedures for Very Early Cancer
The earliest cervical cancers, classified as stage IA1, are often small enough to be removed with a minor outpatient procedure. Two common options are cold knife conization and loop electrosurgical excision (LEEP). Both involve cutting out a cone-shaped piece of tissue from the cervix that contains the cancer, leaving the rest of the reproductive system intact.
Cold knife conization uses a surgical scalpel and is performed under anesthesia. LEEP uses a thin heated wire loop and can sometimes be done in a clinic setting. A meta-analysis comparing the two found similar recurrence rates, with no statistically significant difference between them. In one study, recurrences appeared 5 to 31 months after surgery in roughly 7% to 11% of patients with clear margins on their tissue samples. Your doctor will choose between them based on tumor size, location, and whether a precise tissue sample is needed for further analysis.
If the cancer is IA1 but has features suggesting a higher risk of returning, a total hysterectomy (removal of the uterus and cervix) may be recommended instead. The ovaries can often be left in place, which matters for younger patients who want to avoid early menopause.
Fertility-Sparing Surgery
For patients with early-stage cervical cancer who want to have children in the future, a procedure called radical trachelectomy removes the cervix and surrounding tissue while leaving the uterus in place. This option is typically offered for cancers at stage IB1 or smaller. During the same operation, pelvic lymph nodes are also removed to check whether the cancer has spread.
Pregnancy after trachelectomy is possible but comes with higher risks. In a study from MD Anderson Cancer Center, 70% of pregnancies after trachelectomy resulted in live births. A broader systematic review found that 55% of patients who attempted pregnancy achieved at least one, with a 71% live birth rate among those pregnancies. Premature delivery (before 36 weeks) occurred in about 49% of cases, so close monitoring throughout pregnancy is essential. The cervix plays a structural role in keeping a pregnancy intact, and removing it increases the chance of early labor.
Radical Hysterectomy for Larger Tumors
Stages IB and IIA cancers, where tumors are larger but still mostly confined to the cervix and upper vagina, are commonly treated with radical hysterectomy. This is more extensive than a standard hysterectomy. It removes the uterus, cervix, upper portion of the vagina, and the tissue surrounding the cervix. Pelvic lymph nodes are removed at the same time.
Recovery from radical hysterectomy is significant. Most patients spend several days in the hospital and need six to eight weeks before returning to normal activities. Bladder function can be temporarily affected because nerves that control the bladder run close to the cervix and may be stretched or damaged during surgery. Some patients need a catheter for days to weeks afterward. Lymphedema, swelling in the legs caused by removal of lymph nodes, is another possible long-term side effect.
If the surgical tissue shows concerning features, such as cancer cells at the edges or lymph node involvement, radiation with chemotherapy may be recommended after surgery to reduce the chance of recurrence.
Radiation and Chemotherapy for Advanced Cancer
For stages IIB through IVA, where cancer has spread into the tissues around the cervix or into the pelvis, the standard treatment is radiation and chemotherapy given together. This combination, called chemoradiation, works because the chemotherapy makes cancer cells more vulnerable to the radiation.
Treatment typically involves external beam radiation delivered to the pelvis five days a week, combined with chemotherapy sessions on the same days. This is followed by internal radiation (brachytherapy), where a small radioactive device is placed directly against the cervix to deliver a concentrated dose. The entire course of treatment usually lasts around eight weeks, with a median duration of about 57 days in clinical studies.
Side effects during treatment commonly include fatigue, nausea, diarrhea, and irritation of the bladder and bowel. Most of these improve after treatment ends, but some patients experience long-term changes in bowel or bladder habits, and radiation to the pelvis causes infertility.
Immunotherapy for Recurrent or Metastatic Disease
When cervical cancer comes back after initial treatment or has spread to distant parts of the body, newer immunotherapy options are available. In 2021, the FDA approved the immunotherapy drug pembrolizumab (Keytruda) in combination with chemotherapy for first-line treatment of persistent, recurrent, or metastatic cervical cancer. This applies to tumors that test positive for a protein called PD-L1, which about 90% of cervical cancers express.
In the clinical trial that led to this approval (KEYNOTE-826), patients received pembrolizumab alongside standard chemotherapy, with or without bevacizumab, a drug that blocks blood vessel growth to tumors. The combination showed meaningful improvements in survival compared to chemotherapy alone. Pembrolizumab is also approved as a standalone treatment for patients whose cancer has progressed after chemotherapy, as long as the tumor expresses PD-L1.
These treatments don’t cure most metastatic cervical cancers, but they can extend life and, in some cases, shrink tumors substantially enough to control symptoms for months or years.
What to Expect After Treatment
Follow-up after cervical cancer treatment is intensive in the first two to three years, when recurrence is most likely. This typically involves physical exams and imaging every few months, gradually spacing out over time. For patients who had fertility-sparing surgery, close surveillance is particularly important because the cervix or part of it remains, and new precancerous changes can develop.
Sexual health is a common concern after treatment. Surgery can shorten the vagina, and radiation can cause scarring and dryness that make intercourse uncomfortable. These effects are manageable with dilator therapy, lubricants, and in some cases hormone treatments, but they often require proactive discussion with your care team since they may not be brought up automatically.
Emotional recovery matters too. The combination of a cancer diagnosis, changes to reproductive organs, and the physical toll of treatment affects mental health in ways that can persist long after the cancer itself is gone. Support groups and counseling focused on cancer survivorship can make a meaningful difference during this period.